Destiny Pharma Lancet Report
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Important Lancet report highlights … Continue reading “Destiny Pharma Lancet Report”
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Important Lancet report highlights … Continue reading “Destiny Pharma Lancet Report”
The Hague, Netherlands, 19 January 2022: Amber Implants, an innovative medical technology company … Continue reading “Amber Implants Closes US$10 M Series A Financing”
Emcitate® (tiratricol) is the first potential treatment of MCT8 deficiency, a rare … Continue reading “Egetis concludes that demonstrating treatment effects on T3 levels in MCT8-deficiency could provide a basis for marketing approval for Emcitate® in the US”
Brighton, United Kingdom, 17 January 2022 – Destiny Pharma plc (AIM: DEST), a … Continue reading “Destiny Pharma Strategy/Company/Ops Update”
Over US$ 550 million raised by portfolio companies in 2021 IO Biotech … Continue reading “Novo Seeds Provides Business Update on a Record Year – Building Exceptional Companies for Global Impact”
COPENHAGEN, Denmark, 11 January 2022 – BioInnovation Institute (BII), a non-for profit … Continue reading “BioInnovation Institute Awarded Grant to Launch a New Initiative Focused on Women’s Health”
First company to develop an AI product to predict egg viability with … Continue reading “Future Fertility Raises Series A to Progress First-In-Class AI-Enabled Fertility Solutions to Improve IVF Outcomes”
Youth unemployment in Jordan is record high, and up to 50% of … Continue reading “Novo Holdings – Grant of DKK 200 million will create better future prospects for young Syrian refugees in Jordan”
Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing … Continue reading “Versameb to Attend Biotech Showcase 2022”
ENHANCE-2 Screening Complete with Full Enrollment Expected in January 2022 ENHANCE Phase … Continue reading “Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset”
Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies Genmab secures … Continue reading “Genmab and Synaffix Enter into License Agreement for ADC Technology”
LONDON and RALEIGH, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) — Verona Pharma … Continue reading “Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference”
Copenhagen, Denmark – Novo Holdings, a leading international life sciences investor, today announced … Continue reading “Novo Holdings participates in EUR 110 million first closing of Sound Bioventures Fund I”
Novo Holdings A/S (“Novo Holdings”) today announced that it has agreed to … Continue reading “Novo Holdings to acquire Ritedose”
The use of a biotechnology-based and certified-vegan silk-like fabric marks a first … Continue reading “AMSilk Partners with Mercedes-Benz to Present a Sustainable Bio-Based Product”
OSLO/LONDON, 22 December 2021: Christmas came early at EXACT Therapeutics AS (“EXACT-Tx”, or … Continue reading “EXACT Therapeutics AS Announces Allowance of Patent Application in Europe for Acoustic Cluster Therapy (ACT®)”
COPENHAGEN, DENMARK — Novo Holdings, a leading international life sciences investor, today … Continue reading “Novo Holdings invests EUR 86 million in 21st.BIO, a new bioindustrial scale-up company building on technology base from Novozymes”
OSLO/ LONDON: 21 December 2021: EXACT Therapeutics AS (“EXACT-Tx” or “the Company”, … Continue reading “EXACT Therapeutics AS Awarded NOK 7.4 M Grant for the Development of its Next Generation Ultrasound Transducer and Navigation System for ACT®”
Chord Therapeutics was launched by Omega Funds in October 2020 to develop … Continue reading “Merck Acquires Chord Therapeutics to Expand Neuroinflammatory Pipeline”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2022 Optimum Strategic Communications All rights reserved.
The Spice Building
8 Devonshire Square
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
